UK Markets open in 1 hr 41 mins
  • NIKKEI 225

    28,147.51
    -461.08 (-1.61%)
     
  • HANG SENG

    28,231.04
    +217.23 (+0.78%)
     
  • CRUDE OIL

    63.78
    -2.30 (-3.48%)
     
  • GOLD FUTURES

    1,819.90
    -16.20 (-0.88%)
     
  • DOW

    33,587.66
    -681.50 (-1.99%)
     
  • BTC-GBP

    35,168.46
    -1,171.75 (-3.22%)
     
  • CMC Crypto 200

    1,468.19
    -95.64 (-6.12%)
     
  • Nasdaq

    13,031.68
    -357.75 (-2.67%)
     
  • ^FTAS

    3,986.82
    +23.84 (+0.60%)
     

Hardman & Co Research: Diurnal (DNL): And then there were three

·2-min read

Hardman & Co Research
30-Sep-2020 / 08:15 GMT/BST

Hardman & Co Research: And then there were three

Diurnal is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its products are targeting rare conditions where medical need is currently unmet, with the long-term aim of building an "Adrenal Franchise". Alkindi(R) was approved by the European regulators in September 2018, and has been launched in 10 countries. Now it has been approved for the US market, with Diurnal receiving formal approval from the FDA. This is an important value-inflection milestone that only two other AIM-listed companies have reached. Marketing partner, Eton Pharmaceuticals (Eton), has high US sales expectations.

Please click on the link below for the full report:

https://www.hardmanandco.com/research/corporate-research/and-then-there-were-three/

If you are interested in meeting the company, you can register your interest by clicking on the above link

To contact us:

Hardman & Co
35 New Broad Street
London
EC2M 1NH

www.hardmanandco.com

Follow us on Twitter @HardmanandCo

Contact:

Dr Martin Hall



+44 20 7194 7622

 

mh@hardmanandco.com

 

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: For the past 25 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge.  Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies.  It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

 


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

End of Announcement - EQS News Service

show this
show this